分类： ACN Newswire

香港，2025年9月25日 - (亚太商讯 via SeaPRwire.com) - 近日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）助力复星高科技(集团)有限公司（"复星高科"）成功发行全球首单民营企业"玉兰债"，发行规模10亿元、期限3年、发行利率4.9%。本次项目中，国泰君安国际积极响应国家支持民营经济发展的战略部署，充分发挥专业协调与高效执行能力，通过联动国泰海通总部多个条线，组织投资人反向路演，开展扎实深入的市场推介工作，成功助力企业对接离岸人民币资本市场。本次债券的成功发行是国泰君安国际联合上海清算所，通过"玉兰债"贯彻落实人民银行关于强化综合金融服务能力、创新和丰富民营企业融资渠道要求的生动典范，更是联动金融基础设施协同整合境外资本市场各方力量，畅通民营企业境外融资渠道的最新成果，为民营经济高质量发展注入金融"活水"。展望未来，国泰君安国际将持续深化金融产品与服务创新，拓展跨境融资渠道，助力更多民营企业对接国际资本市场；同时，进一步强化境内外金融基础设施协同，构建更加高效、便捷的金融服务生态，为民营经济发展提供持续、有力的金融支持。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，幷在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球84%同业。公司控股股东国泰海通证券（股票代号：601211.SH/ 2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

费城，宾夕法尼亚州, 2025年9月25日 - (亚太商讯 via SeaPRwire.com) - 作为全球医疗人力资源发展的领导者，TruMerit 正与 EnGen 合作。EnGen 是一款与劳动力发展相结合的英语学习解决方案，旨在帮助海外受训的护士及其他医疗专业人员提升英语技能，从而在英语工作环境中取得成功，并在他们的新社区中茁壮成长。这一全新合作使 TruMerit 现有及往期资质评估服务的申请人能够购买 EnGen 平台的个人使用权，以及其先进的英语技能提升工具。通过有针对性的、与岗位相关的英语培训，学习者将增强自信、提升工作表现，并为在医疗系统中填补关键人力缺口的紧缺岗位做好准备。EnGen 的创新方法结合了按需的、由人工智能驱动的教学与人工支持，其中包括实时在线小组研讨会和辅导课程。该解决方案帮助在职成年人掌握特定岗位和职业路径所需的英语技能，包括医疗岗位。扎实的英语能力不仅有助于他们准备必需的语言水平测试和执业考试，也能推动职业发展，并在新的国家的职场与社区生活中茁壮成长。随着每年成千上万名海外受训的护士及相关医疗专业人员抵达美国，帮助缓解医疗系统的人力短缺，强有力的沟通能力成为关键资产。**它们能够促进更好的协作、提升患者护理质量，并改善整体医疗结果。除了对申请人母国教育与执照进行验证（TruMerit 已经在提供此类服务）之外，美国移民法还要求提供英语水平证明，以确保跨医疗团队的清晰沟通，并保障患者安全。TruMerit 总裁兼首席执行官 Peter Preziosi 博士表示：“在 TruMerit 不断扩展的医疗职业发展重点下，我们坚定致力于帮助移居的护士及其他医疗专业人员在职业生涯的每个阶段都能茁壮成长。在美国，这意味着他们有机会将语言理解从‘熟练’提升到‘精通’。”他补充道：“我们很高兴能与 EnGen 合作来应对这一挑战，通过该公司提供的个性化、以移动端为先的学习体验，让与职业发展相结合的英语培训变得触手可及。”EnGen 创始人兼首席教育官 Katie Brown 博士表示：“通过为海外受训的医疗工作者提供与岗位相关的英语技能，我们正在赋能他们自信地与患者沟通，提供高质量护理，并在高压环境中取得成功——同时在下班后也能在社区生活中蓬勃发展。EnGen 的方法带来了切实成果：94% 的学习者在工作中使用英语时更有信心，93% 的人节省了工作时间，92% 的人提升了工作技能。另有 80% 的人表示他们在日常生活中更加得心应手。我们很自豪能与 TruMerit 携手，共同建设一支更强大、面向未来的医疗人力队伍。”除了以医疗为重点的英语培训外，EnGen 还提供帮助学习者适应英语国家新生活的相关内容，涵盖社会融入、法律、金融和数字素养等主题，以及美国公民入籍考试的备考课程此外，为了帮助随行配偶和其他家庭成员更好地适应，通过 TruMerit 提供的优惠方案中还包含家庭选项的特别价格，14 岁及以上的家庭成员也可使用 EnGen 提供的课程。关于 TruMeritTruMerit 是全球领先的医疗人力发展机构。前身为 CGFNS International，该组织拥有近 50 年历史，致力于协助护理人员与其他医疗工作者——以及负责发照与聘用的机构——在寻求在美国及其他国家执业许可时，验证其教育背景、专业技能与实践经验，促进其职业流动性。作为 TruMerit，该机构的使命已扩展为建立符合全球快速变迁健康需求的人力资源能力。通过旗下的全球健康人力发展研究院（Global Health Workforce Development Institute），TruMerit 正在推动以实证为基础的研究、思想领导与倡议，支持各项医疗人力发展方案，包括全球认可的执业标准与认证，以此强化医疗工作者的职业发展路径。关于 EnGenEnGen 提供了一种可规模化、由人工智能驱动的英语教学方式，旨在解决系统性获取不足的问题：在美国，成年英语学习者已占到劳动年龄人口的十分之一，但现有劳动力体系仅满足了其中约 2% 的需求。作为一家获得认证的 B 型企业，EnGen 正通过与雇主、成人教育机构、劳动力发展组织以及州政府合作，填补这一缺口，帮助求职者和在职员工掌握英语技能、获得职业发展路径，并进入高需求行业就业。EnGen 以劳动力发展为导向的方法，不仅应对了雇主在招聘与留用方面的挑战，也推动了学习者的经济流动性。了解更多信息，请访问 getengen.com。联系信息David St. John dstjohn@trumerit.org来源: TruMerit Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PALO ALTO, CA, Sept 25, 2025 - (ACN Newswire via SeaPRwire.com) - Nanofiber Quantum Technologies, Inc. (NanoQT), a quantum computing company pioneering ultra-low-loss nanofiber cavity-QED interconnects for quantum processors, today announced the first closing of its $14 million Series A financing. Phoenix Venture Partners (PVP), an existing investor, led the round with participation from Brevan Howard Macro Venture Fund, a new investor. WASEDA University Ventures, Inc. (WUV), JAFCO Group Co Ltd, Mirai Creation Fund III (SPARX Asset Management Co., Ltd.), and Keio Innovation Initiative, Inc. (KII), each existing investors, also participated.NanoQT’s Proprietary Nanofiber-CavityThe financing follows more than US$20 million in government R&D grants across Japan and the United States that support NanoQT's roadmap. "An interconnect engineered for QPUs is the missing link in today's market and will soon be a major bottleneck to achieving scalable fault-tolerant quantum computing," said Masashi Hirose, Ph.D., CEO and Co-Founder of NanoQT. "Our proprietary nanofiber-cavity interconnect is highly demanded not only for scaling up quantum computing but also for integrating QPUs with quantum communication capabilities.""We are delighted to continue supporting NanoQT's breakthrough," said Nobi Kambe, Ph.D., Managing General Partner at Phoenix Venture Partners (PVP). "NanoQT has demonstrated steady R&D progress, and we believe the company will deliver a disruptive impact in the quantum computing and networking field." "NanoQT is the best positioned in the quantum field to disrupt interconnects."Why It MattersThe quantum interconnect is an emerging, critical device class-essential not only for modularizing quantum processors but also for extending them into networked and communication-enabled systems. NanoQT's approach is an ultra-low-loss nanofiber cavity that functions as an end-to-end fiber-optic interconnect, enabling extremely efficient conversion of qubit signals into photonic signals-a capability fundamentally grounded in cavity quantum electrodynamics (QED).NanoQT's initial product is highly engineered for neutral-atom QPUs, which today represent one of the most scalable quantum computing architectures. Yet these systems will face per-unit scalability limits within a few years. NanoQT's interconnect provides a path beyond those limits, while also positioning the company to address the emerging quantum repeater market, which is essential for building long-distance quantum networks.Use of Proceeds and Next MilestonesDemonstration of a distributed quantum computing system using NanoQT's interconnect and standard fiber linksProductization of the nanofiber cavity-QED interconnect for neutral-atom QPUsExpansion of engineering and manufacturing capacity in College Park, Maryland, and TokyoAbout NanoQTNanoQT is a quantum-hardware company building ultra-low-loss nanofiber cavity-QED interconnects that physically integrate with quantum processors to enable modular and networked quantum computing as well as compatibility with quantum communication. Headquartered in Palo Alto, California, with operations in College Park, Maryland and Tokyo, Japan, NanoQT combines Japan-born engineering excellence with a global commercialization strategy.Learn more: www.nano-qt.comContact InformationDai TsukadaHead of Operationsinfo@nano-qt.comSOURCE: Nanofiber Quantum Technologies, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA, Sept 25, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit, a leader in global healthcare workforce development, is partnering with EnGen, a workforce-aligned English language learning solution, to support foreign-educated nurses and other healthcare professionals in building the language skills to succeed in English-speaking work environments and to flourish in their new communities.This new collaboration enables current and past applicants for TruMerit's credential evaluation services to purchase individual access to EnGen's platform and state-of-the-art tools for building English skills. Through targeted, job-specific English training, learners will boost their confidence, enhance their job performance, and prepare for in-demand roles in healthcare systems facing critical staffing shortages.EnGen's innovative approach blends on-demand, AI-powered instruction with human-mediated support, including live online group workshops and coaching. The solution equips working adults with the English skills needed for specific jobs and career paths, including healthcare roles. Stronger English skills not only help them prepare for required language proficiency tests and licensure exams, but also to grow in their careers and thrive in workplace and community life in their new country.With thousands of foreign-educated nurses and allied professionals arriving in the U.S. each year to help fill staffing shortages in health systems, strong communication skills are a vital asset, enabling better collaboration, patient care, and overall outcomes. In addition to verification of their education and licensing in their home countries-services that TruMerit already provides-U.S. immigration law requires proof of English language proficiency to ensure clear communication across the healthcare teams and protect patient safety."Under TruMerit's expanded focus on healthcare career development, we are determined to help migrating nurses and other health professionals thrive at every stage of their careers. In the U.S., this means having the opportunity to take their understanding of the language from proficiency to mastery," said Dr. Peter Preziosi, President and CEO of TruMerit."We are delighted to be able to work with EnGen to address this challenge by making career-aligned English instruction available through the personalized, mobile-first learning experiences the company offers," he said."By equipping foreign-educated healthcare workers with job-specific English skills, we're empowering them to communicate confidently with patients, deliver high-quality care, and succeed in high-stakes environments-while also thriving off the clock in their communities," said Dr. Katie Brown, EnGen's Founder and Chief Education Officer. "EnGen's approach drives real-world results: 94% of our learners feel more confident using English at work, 93% save time on the job, and 92% have improved their job skills. Another 80% said they can navigate life better. We're proud to partner with TruMerit to help build a stronger, future-ready healthcare workforce."In addition to the healthcare-focused English instruction, EnGen also offers content aimed at helping learners navigate their new life in an English-speaking country, covering topics like social integration, legal, financial, and digital literacy, as well as U.S. citizenship test preparation.Additionally, to help accompanying spouses and other family members adjust, the offers available through TruMerit include special pricing on a family option, under which courses offered by EnGen can be accessed by family members aged 14 and above.About TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers-and those who license and hire them-by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers.About EnGenEnGen offers an at-scale, AI-powered approach to English instruction, designed to solve a systemic access issue: Adult English learners now represent 1 in 10 working-age adults in the U.S., yet the workforce system serves the needs of just 2% of these workers. A Certified B Corporation, EnGen is filling the gap by partnering with employers, adult educators, workforce development organizations, and state governments to connect job seekers and incumbent workers with English skills, career pathways, and employment in high-demand industries. EnGen's workforce-aligned approach addresses employers' recruitment and retention challenges and advances learners' economic mobility. Learn more at getengen.com.Contact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Key Takeaways:WORK Medical has formed a new alliance with the Hong Kong Web3.0 Standardization Association and was appointed as the organization’s “council vice chairman.”The company has also entered into a collaboration with Ruijin Hospital’s Wuxi Branch to accelerate the development of a next-generation, AI-driven smart clinical ecosystemHONG KONG, Sep 24, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong kicked off a new era in its embrace of virtual assets on Aug. 1 with the official launch of a regulatory and licensing framework for virtual currencies known as stablecoins. A steady stream of Chinese companies has begun experimenting in the city with virtual assets and their underlying blockchain technology since then, covering a wide range of industries.Medical products seller WORK Medical Technology Group Ltd. (WOK.US) became the latest to join that parade, as it unveiled a major new initiative to explore real world asset (RWA) tokenization and related blockchain technology in a partnership with the Hong Kong Web3.0 Standardization Association, which promotes the high-quality development of the global Web3.0 industry through standardization research and efforts.The deal comes just over a year after WORK Medical listed on the Nasdaq, and is part of the company’s evolving “Healthcare + Payment + Technology = RWA + Web3 + AI” strategy. WORK Medical also plans to strategically collaborate with one or more qualified firms from the financial sector, which would provide a key compliance channel for its asset tokenization ambitions.Tokenized RWA, or real-world assets with value that have been digitalized, is projected to surge to over $50 billion by the end of this year, according to a report published in May by digital currency market-making firm Keyrock and tokenization platform Centrifuge. The report also pointed out that tokenized RWA will be dominated by U.S. treasuries, whose value alone will push the sector size to over $28 billion.  Three areas for collaborationWORK Medical laid out three main areas for collaboration with its new Hong Kong partner. The first area involves the tokenization of “high-quality assets owned or invested in by WORK Medical,” the company said. It pointed out it can leverage both its status as a Nasdaq-listed company, as well as its expertise and assets related to its medical device business, including AI healthcare assets. It wasn’t more specific, but assets it could probably tokenize might include its receivables, investment products and intellectual property.The second area WORK Medical’s new partnership will explore is equity investments, which could include co-investments or participation in funds and other financial vehicles to accelerate its move into RWA for potential tokenization and achieve shared strategic goals.The third area involves development of RWA technology, which would leverage the Hong Kong Web30 Association’s recently launched RWA registration platform. That platform facilitates collaboration on a range of related functions, including blockchain-based title verification, asset issuance, and cross-chain transactions, while ensuring regulatory compliance and asset security.The company’s recent activities indicate it is already accumulating the expertise to develop and manage such assets. In February, it announced a partnership with another medical device company that included the potential establishment of “joint investment funds to align industrial and financial resources.” It said that partnership could also involve investment in healthcare infrastructure, development of advanced technologies and global acquisitions.WORK Medical’s new partnership puts it at the head of a nascent but rapidly growing wave of Chinese companies looking for new business opportunities in the fast-emerging business of digitalized RWAs. Any company owning or possessing rights to RWAs, both their own and assets owned by others, can technically enter the space.Building smart clinical ecosystemOn Monday, WORK Medical also announced another new partnership with the Wuxi Branch of the Ruijin Hospital-Shanghai Jiao Tong University School of Medicine. Under the partnership, WORK Medical will support Xin Rui Hospital’s efforts to advance hospital informatization. It will also assist in efforts to integrate AI with the hospital’s multimodal medical data, such as text, imaging, and lab results.https://www.globenewswire.com/news-release/2025/09/22/3153945/0/en/WORK-Medical-Technology-Group-LTD-Partners-with-Wuxi-Branch-of-Ruijin-Hospital-Shanghai-Jiao-Tong-University-School-of-Medicine-to-Develop-AI-Applications-in-Healthcare.htmlThe two sides plan to enhance WORK Medical’s multimodal AI solutions from single-image to complex data types by leveraging Xin Rui Hospital’s clinical and expert resources. The collaboration aims to develop AI models for diverse healthcare scenarios, establishing a framework for data governance, model training, and clinical translation. WORK Medical Chairman and CEO Wu Shuang said the two new partnerships – with the Hong Kong Web3.0 Standardization Association for RWA innovation and with Xin Rui Hospital for AI-driven healthcare – are strategic moves aimed at unlocking new growth avenues and building long-term value.The company’s inaugural annual earnings report for its fiscal year through September 2024, issued earlier this year, also contains hints that it was dabbling in financial markets, not only through its IPO but also through other investing activities, in the year before its listing.https://www.prnewswire.com/news-releases/work-medical-technology-group-ltd-reports-financial-results-for-fiscal-year-2024-302377075.htmlWORK Medical’s new alliance could take it in a completely new direction from its core business of producing and selling masks and other medical products like artery compression tourniquets. As the Covid pandemic receded and demand for masks declined, leading to falling prices, the company’s revenue from its mask business fell 69% in its fiscal year through September 2024 to $1.6 million from $5.1 million the previous year. That was partly offset by an 18% increase in its revenue for other medical devices, which rose to $9.4 million from $8 million.Its latest financial report also shows that WORK Medical has engaged in commodities trading, which generated $400,000 in income in its latest fiscal year through September 2024. The company also derived a sizable $15.7 million in cash from financing activities for the fiscal year, up sharply from a year earlier and greater than the $11.5 million in revenue it generated from sales of its core medical products for the year.In the finance sector, supply chain financier Linklogis late last month also formed a partnership with XRP Ledger, the organization overseeing the ripple cryptocurrency, aimed at exploring the digitalization and tokenization of RWA.Source: The Bamboo WorksBy Doug Young Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

EIGHTH EDITION OF THE PRESTIGIOUS AWARDS RECOGNISES PROJECTS WITH DOMESTIC AND CROSS-BORDER ASIAN APPEALSYDNEY, AU, Sept 24, 2025 - (ACN Newswire via SeaPRwire.com) - PropertyGuru Group, Southeast Asia’s leading property technology company, celebrated the Gold Standard of Australian real estate in style with the 8th PropertyGuru Asia Property Awards (Australia), supported by Sub-Zero and Wolf.Presented across 20 categories, the PropertyGuru Asia Property Awards (Australia) distinguished outstanding companies and projects from New South Wales, Victoria, Queensland, Western Australia, and beyond. This year marked the inaugural New South Wales gala of the esteemed programme, held at the Shangri-La Sydney.With six wins, Eterno Property Group is the year’s most awarded company, receiving the coveted Best Developer title. Its new project, The Newlands, won two golden statuettes, including the prestigious Best Apartment Development (Australia) award. The company also won for its apartment developments Ode Double Bay and Munro House, as well as the Eterno Head Office.Kuber Projects earned three wins, including Best Breakthrough Developer, accompanied by golden statuettes for its housing developments Kuber Villas, Mandurah and Kuber Villas, Golden Bay.Skyland Group was named Best Luxury Developer (New South Wales), spotlighted by its award-winning Sydney development Eliza Darling Point. Travis Su, managing partner of Skyland Group, received the programme’s first Rising Star award in Australia for championing sustainable luxury and refining low-impact living.Dr. Bay Yeo, founder and group managing director of Exal Group, was honoured as Real Estate Personality of the Year. The distinction celebrates his community-focused projects, including Exal’s remarkable student housing initiatives, combining engineering expertise with sustainable, owner-centric design.This year’s edition of the PropertyGuru Asia Property Awards (Australia) also honoured the country’s sublime waterfront developments, led by The Dunes, Scarborough by Edge Visionary Living and Wanda View by 16MC Developments. Similarly, Eve Residences by Homecorp was celebrated for its impressive ocean views.Queensland projects Maris by MRCB International and Glam by YHY Group garnered honours while Victoria was represented by the award-winning project First Light by DCF Property Group. Third.i Group won for Elevate Hume Place, cited for its direct Sydney Metro access.Jules Kay, general manager of PropertyGuru Asia Property Awards and Events, said: “This year’s winners showcase what makes Australian property stand out internationally—whether it’s for buyers of quality homes, or those looking for a safe and appealing investment. From our Asia Connect events in Melbourne and Brisbane, through to the Sydney gala, we have seen the appetite for Australian real estate remain strong, both at home and abroad. Across modern cities and along stunning coastlines, these award-winning developers are setting new benchmarks for liveability, creating properties in prime locations with the kind of views and surroundings that make Australia a truly iconic destination.”Ivan Lam, chairperson of the PropertyGuru Asia Property Awards (Australia) and executive director for international business at Charter Keck Cramer, said: “We applaud this year’s winners on developing and designing the finest real estate in Australia. These achievements address crucial market gaps and dynamic demographic shifts, catering to the modern property seeker’s desire for connectivity, central locations, and proximity to the country’s natural beauty. Our winners have envisioned outstanding built spaces for diverse property seekers, whether they are investors seeking great returns or those pursuing an amazing lifestyle. From master-planned communities to luxurious residences, award-winning Australian developers offer a wide range of choices for everybody.”An independent panel of judges selected this year’s awardees: Ivan Lam; Lui Violanti, vice-chairperson of the PropertyGuru Asia Property Awards (Australia) and regional manager for Western Australia at Inhabit Group; Amelia (Dan) Tian, director, W T Newey & Co.; Benson Zhou, director – Hotels, CBD and Metropolitan Sales, State Head – Asia Markets, Savills Australia; Jackson Liew, director, Cameron Chisholm Nicol; Karen Kong, head of property lending, Bendigo Bank; Karl Fu, partner – Asian Markets, Winning Commercial; Michelle Tay, group executive director, The SILC Group; Peter Li, general manager, Plus Agency; Richard Newling Ward, director, BayleyWard; Shanker Ramakrishnan, director, SR Business & Finance Consulting; Shona Leppӓnen-Gibson, president, general manager, Australia Malaysia Business Council Queensland Inc, Australian Leadership Skills Centre; and Steven Yu, founder and CEO, Valorton Group.HLB International Real Estate Group supervised the selection process with oversight by Josh Chye, partner and head of tax at HLB Mann Judd, maintaining the awards’ reputation for fairness, transparency, and credibility.The 8th PropertyGuru Asia Property Awards (Australia) is part of the PropertyGuru Asia Property Awards series, which marks its 20th edition in 2025. The series has expanded over the decades from its home in Thailand to markets such as the Middle East, Mainland China, Hong Kong, Macau, Japan, India, Sri Lanka, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, and Vietnam.Top winners of the PropertyGuru Asia Property Awards (Australia) will advance to the PropertyGuru Asia Property Awards Grand Final on 12 December 2025 in Bangkok.The 8th PropertyGuru Asia Property Awards (Australia) is supported by silver sponsor Sub-Zero and Wolf; official portal partner PropertyGuru; supporting associations Australasia Property Advisory Association (APAA), Australia Malaysia Business Council – Victoria (AMBC-Vic), Australia Malaysia Business Council – QLD (AMBCQ), and Australian Property Developers Association (APDA); official magazine Property Report by PropertyGuru; media partners Australian Property Investor, Fang.com.au, Inside Queensland Daily, PhilTimes.com.au, Sydney Today, The Property Tribune, and Your Investment Property; and official supervisor HLB.For more information, email awards@propertyguru.com or visit the official website: AsiaPropertyAwards.com.COMPLETE LIST OF WINNERS8th PropertyGuru Asia Property Awards (Australia)DEVELOPER AWARDSBest DeveloperWINNER: Eterno Property GroupBest Luxury Developer (New South Wales)WINNER: Skyland GroupBest Breakthrough Developer WINNER: Kuber ProjectsDEVELOPMENT AWARDSBest Luxury Apartment Development (New South Wales)WINNER: Ode Double Bay by Eterno Property GroupHIGHLY COMMENDED: Elevate Hume Place by Third.i GroupBest Luxury Boutique Apartment Development (New South Wales) WINNER: Eliza Darling Point by Skyland GroupBest Luxury Apartment Development (Victoria)WINNER: First Light by DCF Property GroupBest Apartment Development (Queensland)WINNER: Maris by MRCB InternationalBest Waterfront Apartment Development WINNER: The Dunes, Scarborough by Edge Visionary LivingBest Low Rise Waterfront Apartment DevelopmentWINNER: Wanda View by 16MC DevelopmentsBest Oceanview Apartment DevelopmentWINNER: Eve Residences by HomecorpBest Connectivity Apartment DevelopmentWINNER: Elevate Hume Place by Third.i GroupBest Completed Apartment DevelopmentWINNER: Munro House by Eterno Property GroupBest Housing Development (Western Australia)    WINNER: Kuber Villas, Mandurah by Kuber ProjectsBest Investment Housing DevelopmentWINNER: Kuber Villas, Golden Bay by Kuber ProjectsBest Nature Integrated DevelopmentWINNER: The Newlands by Eterno Property GroupDESIGN AWARDSBest Luxury Apartment Architectural Design (Queensland) WINNER: Glam by YHY GroupBest Office Interior Design    WINNER: Eterno Head Office by Eterno Property GroupBEST OF AUSTRALIABest Apartment Development (Australia)WINNER: The Newlands by Eterno Property GroupINDIVIDUAL AWARDSReal Estate Personality of the YearWINNER: Dr. Bay Yeo, Founder & Group Managing Director, Exal GroupRising StarWINNER: Travis Su, Managing Partner, Skyland GroupNOTE: Use of the PropertyGuru Asia Property Awards logo is limited to the publication of this article only.ABOUT PROPERTYGURU ASIA PROPERTY AWARDS:PropertyGuru’s Asia Property Awards, established in 2005, are the region’s most exclusive and prestigious real estate awards programme. The Asia Property Awards are recognised as the ultimate hallmark of excellence in the Asian property sector. Boasting an independent panel of industry experts and trusted supervisors, the Awards have an unparalleled reputation for being credible, ethical, fair, and transparent. In 2025, the Awards series is open to key property markets around the region. The exciting gala events welcome senior industry leaders and top media, as well as reach property agents and consumers via live streaming. Recognising excellence within each Asian market with a variety of categories, including green and sustainable development, each local awards programme will culminate in the PropertyGuru Asia Property Awards Grand Final, which takes place after the PropertyGuru Asia Real Estate Summit during PropertyGuru Week in December 2025. For more information, please visit AsiaPropertyAwards.com.ABOUT PROPERTYGURU GROUP:PropertyGuru is Southeast Asia’s leading1 PropTech company, and the preferred destination for over 32 million property seekers monthly2 to connect with over 50,000 agents3 monthly to find their dream home. PropertyGuru empowers property seekers with more than 2.1 million real estate listings4, in-depth insights, and solutions that enable them to make confident property decisions across Singapore, Malaysia, Thailand, and Vietnam.PropertyGuru.com.sg was launched in Singapore in 2007 and since then, PropertyGuru Group has made the property journey a transparent one for property seekers in Southeast Asia. In the last 18 years, PropertyGuru has grown into a high-growth PropTech company with a robust portfolio including leading property marketplaces and award-winning mobile apps across its markets in Singapore, Malaysia, Vietnam, and Thailand as well as the region’s biggest and most respected industry recognition platform – PropertyGuru Asia Property Awards, events, and publications across Asia.For more information, please visit: PropertyGuruGroup.com; PropertyGuru Group on LinkedIn.(1) Based on SimilarWeb data between July 2024 and December 2024.(2) Based on Google Analytics data between July 2024 and December 2024.(3) Based on data between October 2024 and December 2024.(4) Based on data between July 2024 and December 2024.PROPERTYGURU CONTACTS:General Enquiries:Richard Allan Aquino, Head of Brand & Marketing ServicesM: +66 92 954 4154E: allan@propertyguru.com  Sales & Nominations:Watcharaphon Chaisuk (Jeff), Solutions ManagerM: +66 95 797 0595E: jeff@propertyguru.comMedia & Partnerships:Nate Dacua, Senior Manager, Media and Marketing ServicesM: +66 92 701 2510E: nate@propertyguru.comSales & Nominations:Monika Singh, Solutions ManagerM: +66 87 677 4812E: monika@propertyguru.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月24日 - (亚太商讯 via SeaPRwire.com) - 从深交所到港交所：格林美携关键金属资源回收、电池回收、新能源材料制造三大核心业务，开启全球化新局。自去年以来，A+H 股上市热潮持续升温，越来越多深耕细分领域的龙头企业选择通过两地上市拓宽融资管道、提升国际竞争力。新能源产业作为全球战略核心赛道，更是成为这股热潮中的焦点。9月22日，循环经济与新能源材料领域的领军企业格林美股份有限公司（格林美，002340.SZ），向港交所递交上市申请，拟开启 A+H 股双资本平台布局。自2001年成立以来，格林美利用循环领域的技术优势，开启了以镍钴回收再制造为主的关键金属循环业务模式。2010年，公司在深交所上市。此次赴港上市，不仅是对其行业地位的巩固，更标志着其开启对接全球资本、拓展国际业务的全新篇章。三大核心业务驱动构建竞争壁垒，全球市场份额领先在关键金属回收领域，格林美聚焦镍、钴、锂、钨、铜、铂等关键矿产资源循环，实现20余种关键矿产资源的再生制造，有效减少原生矿产开采需求，践行循环经济理念。据弗若斯特沙利文资料，以2024年回收量计，公司在中国镍、钴、钨资源回收领域排名第一，成为国内城市矿山开发的核心力量。其印尼Morowali生产基地氢氧化镍钴（MHP）年产能达15万吨，以2024 年MHP权益产量计，格林美跻身全球前三。在动力电池回收业务方面，公司第三方退役锂离子电池回收量亦位列中国首位，拥有6家工信部（MIIT）白名单回收企业，全球回收工厂遍布中国、韩国、印尼，在2025年，公司与欧美领先的回收公司签署MOU，谋划在欧洲等地建设锂动力电池回收工厂与共建镍钴锂关键资源回收体系，构建全球化锂动力电池与镍钴锂资源回收体系。基于回收领域领先优势，格林美于2012年战略性拓展下游新能源材料行业，构建了「镍资源-前驱体-正极材料」的镍资源新能源全产业链，关键产品领域市场地位全球领先。在三元前驱体及正极材料方面，格林美拥有覆盖NCM、 NCA全系主流产品的全面产品组合，是全球首家实现9系超高镍核壳三元及四元前驱体量产出货的企业。根据弗若斯特沙利文资料，以2024年的出货量计，格林美是全球第二大三元前驱体生产商，同时也是全球最大的高镍三元前驱体生产商。此外，3C电子产品电池用的四氧化三钴材料全球市占率超过20%。通过打通从资源回收到新能源电池材料制造的闭环，实现关键原材料的自给自足，格林美在新能源材料领域形成了难以复制的商业壁垒。目前，格林美已与全球十大锂离子电池企业中的九家建立了长期稳定的合作关系，并与全球超过1,000家汽车企业及电池制造商建立合作关系，在第三方退役锂离子电池回收领域回收率位居中国第一。业绩增长稳健，海外市场贡献持续提升在双轨驱动业务模式的推动下，格林美实现经营业绩的稳健增长。2022年至2024年，公司营收分别达人民币293.92亿元、305.29 亿元、331.99 亿元，连续三年保持增长，展现出强劲的经营韧性。2025年上半年，公司营收达175.61亿元，延续增长势头。盈利方面，同期公司EBITDA从32.84亿元增至41.07亿元，并于2025年上半年进一步增至24.51亿元，盈利能力稳中有升，为业务扩张提供有力支撑。值得关注的是，格林美海外市场拓展成效显著，全球化布局逐步深化。2024 年，公司海外营收占比为 23.6%，而 2025 年上半年这一比例已提升至 31.5%，大幅增长近 8 个百分点，反映出其产品在国际市场的认可度持续提升，海外业务已成为公司重要的增长引擎。随着全球新能源产业与循环经济需求的持续爆发，公司海外市场份额有望进一步扩大，为长期增长注入新动能。从行业维度看，全球新能源产业正处于高速扩张期，带动新能源材料需求不断提升。而资源约束与环保要求的双重压力，推动「循环经济」成为产业链可持续发展的核心方向，根据弗若斯特沙利文数据，再生镍、钴、锂等关键金属需求量占比将持续提升。​同时，退役锂离子电池的数量不断增加也为回收业务创造了巨大机遇。格林美凭借「循环回收」模式，既占据资源回收的环保赛道，又切入新能源材料的高增长赛道，竞争优势显著，有望成为行业政策红利的直接受益者。此次赴港上市，藉助A+H 股双平台布局，公司有望进一步扩大产能、深化研发，强化全球产业链地位，为长期价值增长注入更强的确定性。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月24日 - (亚太商讯 via SeaPRwire.com) - 近年来，地缘政治不确定性加剧、全球货币宽松周期频发，黄金的避险属性与金融属性愈发凸显，成为全球央行与投资者的重要配置资产。2025年以来，国际金价持续上扬，不断刷新历史高位，截至9月18日，国际现货黄金价格累计涨约40%。在地缘政治、经济冲突、货币体系动荡等结构性因素未根本改变，迭加央行购金、投资需求等支撑，黄金资产中长期配置价值持续凸显，黄金开采企业将从中受益。紫金黄金国际有限公司（「紫金黄金国际」，股份代号：2259.HK）作为紫金矿业海外黄金资产整合平台，承接了紫金矿业（601899.SH，02899.HK）在中国境外的全部8座黄金矿山，业务覆盖中亚、南美洲、大洋洲及非洲等黄金资源富集区，有望凭借独特优势承接行业红利。9月19日，紫金黄金国际启动港股招股，招股价每股71.59港元，按每手100股计，入场费7,231.19港元，摩根士丹利及中信证券为联席保荐人。收并购能力驱动快速扩张，打造全球市场领先地位过去近20年，紫金黄金国际聚焦高潜力黄金矿山及价值被低估的低品位、难选冶黄金矿山，在南美洲、大洋洲、中亚和非洲等黄金资源富集区完成多起关键收购，迅速搭建起多元化黄金矿山资产组合。这一扩张路径的成功，离不开其卓越的并购能力与紫金矿业的深度协同支撑。依托紫金矿业全球领先的矿业公司地位，借助其丰富的大型金属矿山勘查建设运营经验并辅以自身专业高效的资源并购和勘查能力，紫金黄金国际能够准确识别并收购全球范围内的潜在高价值资产，并在收购完成后以具成本效益方式，积极利用强大的内部能力进行自主地质勘查和开发，从而在不断变化的黄金行业中稳步扩大资源和产量，同时保持低成本和高效率。在并购成本控制上，2019-2024年，紫金黄金国际按黄金资源计的平均收购成本仅约为每盎司61.3美元，较同期每盎司92.9美元的行业平均水平低34%。而在并购后整合环节，公司「识别价值-提升价值」的能力尤为突出，苏里南罗斯贝尔金矿、塔吉克斯坦吉劳╱塔罗金矿和圭亚那奥罗拉金矿等多个收购前亏损的矿山，在收购后1-2年内即实现扭亏为盈，充分验证了其整合效率与运营实力。凭借高效的并购扩张与精益运营，紫金黄金国际的全球市场地位持续提升。截至2024年底，公司黄金储量达27.5百万盎司（856.0 吨），位列全球第九；2024 年黄金产量达1.3百万盎司（40.4吨），排名全球第十一位。2022-2024年，公司黄金产量复合年增长率高达21.4%，在全球大型公司中增速领先，成为行业内名副其实的「增长先锋」。技术与成本优势构筑竞争壁垒 赋能长期盈利增长在黄金开采行业资源品位下降、开采成本上升的趋势下，技术实力与成本控制能力成为企业核心竞争力的关键。紫金黄金国际凭借与紫金矿业的技术协同、自主创新的工艺突破，以及精细化的成本管理，构筑起坚实的竞争壁垒，为长期盈利增长提供强劲支撑。技术层面，紫金黄金国际承袭紫金矿业低品位、难选冶资源开发技术，并广泛利用热压预氧化和生物浸出等专有技术，有效开发利用低品位难处理矿石，显著提升了矿山经济价值。以塔罗金矿为例，该矿矿石含铜、银、砷、碳、硫等多种元素，且金的嵌布粒度微细，开发难度极大，公司针对性开发了含砷含碳金精矿及铜精矿POX工艺技术，解决了金矿难选冶的问题，使其黄金回收率在2022年至2024年由78%提升至81%，2023年建成的精炼厂应用紫金矿业技术后，塔吉克斯坦吉劳╱塔罗金矿产生额外利润约5700万美元。在勘探环节，紫金黄金国际利用控股股东紫金矿业的先进地质勘查技术和自主研发设备，通过整合该等尖端技术和设备，以较低成本实现显著增储。2019年至2025年上半年，公司于此期间运营的矿山的黄金资源量平均勘探成本低至11.7美元╱盎司，远低于同期行业平均的32.3美元╱盎司，持续夯实资源基础。成本控制方面，紫金黄金国际采用紫金矿业独创的「矿石流五环归一」矿山项目管理程序，统筹勘查、采矿、选矿、冶炼和环境保护五大环节，有效降低建设生产成本，实现项目经济社会效益最大化。2024年，公司全维持成本（AISC）为每盎司1,458美元，在全球前十五大黄金开采公司中排名第六低；2022至2024年及2025年上半年，公司运营的七个矿山中，每吨矿石开采成本分别为38.7美元、31.3美元、34.3美元及32.7美元，每吨磨矿选矿成本分别为20.6美元、18.2美元、19.4美元及17.2美元，低成本优势显著。成本优势直接推动盈利水平提升。2022-2024年，紫金黄金国际归母净利润分别为183.7百万美元、230.4百万美元及481.4百万美元，复合年增长率达61.9%，增长势头强劲。2024年股本回报率（ROE）达21.4%，保持较高的资本回报，「技术降本-盈利提升」 的良性循环已经形成。在黄金资产稀缺性加剧、行业集中度提升的趋势下，紫金黄金国际凭借低溢价并购的扩张能力，技术驱动的成本优势、以及与紫金矿业的深度协同，已成长为全球黄金开采行业的增长黑马，展现出强劲的发展韧性与投资价值。当前公司正在港股招股，作为连接全球资本与优质黄金资产的重要目标，有望为市场提供兼具成长潜力与收益稳定性的投资选择。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 24, 2025 - (ACN Newswire via SeaPRwire.com) – September 23, Galaxy Payroll Group Limited (Nasdaq: GLXG) ("Galaxy" or the "Company"), a leading global payroll provider, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC ("Nasdaq").On March 17, 2025, the Company received a written notification from the Nasdaq Listing Qualifications staff, informing the Company that its ordinary shares had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market.Since then, the Company has taken active measures to address this issue and has successfully regained compliance. Specifically, for the last 10 consecutive business days, from September 8 through September 19, 2025, the closing bid price of the Company's ordinary shares has been at $1.00 per share or greater. Accordingly, Nasdaq has formally notified the Company that it has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.Mr. Wai Hong Lao, Chief Executive Officer of Galaxy Payroll Group Limited, commented, "We are pleased to have successfully regained compliance with Nasdaq's minimum bid price requirement well ahead of the stipulated deadline. This positive momentum reflects growing confidence in our business strategy and operational execution. Our focus remains on driving long-term growth and creating sustainable value for our shareholders."About Galaxy Payroll Group LimitedGalaxy Payroll Group Limited is a leading payroll outsourcing service provider based in Hong Kong. The company specializes in delivering HR and payroll solutions to multinational companies across various industries. With a focus on innovation and client satisfaction, GLXG operates in Hong Kong, Taiwan, Macau, and the PRC, offering payroll outsourcing, employment services, and consultancy to businesses of all sizes.For more information, please visit Galaxy Payroll Group's website: www.galaxyapac.com.Forward-Looking StatementsMatters discussed in this press release may constitute forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "anticipate," "intends," "estimate," "potential," "may," "should," "expect" "pending" and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations.For enquiry, please contact Intelligent Joy Limited:Karen DengPhone: (852) 3594 6407Email: pr-team@intelligentjoy.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Highlights:Anson Resources (via its 100% owned subsidiary A1 Lithium) and LG Energy Solution have executed a Definitive Offtake Agreement ("Definitive Offtake Agreement") for the supply of battery grade lithium carbonate from Anson Resources' 100% owned Project within the Paradox Basin.Subject to the satisfaction of customary conditions precedent (summarised in the annexure), the Initial 5-year term is expected to commence in 2028, with the ability to extend for a further five years.LG Energy Solution to purchase 4,000 dry metric tonnes per year and specifies the operational and logistical requirements for the delivery of product.Pricing is determined using a formula-based mechanism referencing market prices for battery-grade Lithium Carbonate.LG Energy Solution is a leading global manufacturer of lithium-ion batteries for electric vehicles, mobility, IT, and energy storage systems.NEWPORT BEACH, CA, Sept 24, 2025 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson Resources" or "the Company") is pleased to announce that it has completed negotiations with LG Energy Solution and on the Definitive Offtake Agreement for the supply of battery-grade Lithium Carbonate from its 100% owned Project within the Paradox Basin in Southern Utah.The Definitive Offtake Agreement provides for the supply of up to 4,000 dry metric tonnes per annum (tpa) of battery-grade Lithium Carbonate produced at the Project, expected to commence in 2028, representing approximately 40% of the Project start-up production capacity of ~10,000tpa.LG Energy Solution is an ideal partner for Anson Resources with its diversified customer base of tier one OEMs and energy storage solutions (ESS) and strong investment to expanding production in North America. LG Energy Solution has eight facilities currently operating or under construction in North America, with stand-alone facilities in Michigan and Arizona and five joint venture facilities with major automakers.Signing of the Definitive Offtake Agreement with LG Energy Solution marks another key milestone for the Company's develops in the Paradox Basin. This Definitive Offtake Agreement will become effective subject to Anson Resources commencement of commercial production in the Paradox Basin and offtake product qualification with LG Energy Solution.The Paradox Basin is a globally significant lithium asset, which the Company through its 100% owned USA subsidiary A1 Lithium, is working to develop into one of the largest lithium resources in the United States. The Company is conducting exploration and test work of the brine, that is known to exist, across multiple areas in the Paradox formation. This work is on-going and if successful will support the Company's theory that the brines of the Paradox Basin contain one of the largest lithium resources in North America.This Definitive Offtake Agreement is also an essential part of the critical path for debt funding at the Final Investment Decision stage.Anson Resources Executive Chairman and Managing Director Bruce Richardson commented:"Anson is delighted to have concluded our definitive offtake agreement with LG Energy Solution for at least 40% of our production. LG Energy Solution not only has a diversified customer base of tier one OEM's they also have many energy storage solutions (ESS) customers.Anson recognized the unstoppable paradigm shift in the US supply chain for electric vehicle battery materials and ESS and the key role that Korean battery manufacturers are playing.This shift in manufacturing investment has led to an increased demand for lithium produced in the US, not only to shorten supply chains geographically but also increase US content of electric vehicle batteries and electric vehicles,Anson identified this change, targeted its offtake marketing activities to the companies that have made these investments into North America and in particular, the US where Anson development work in the Paradox Basin in Southern Utah is strategically positioned.This definitive offtake agreement establishes the foundation for a long-term partnership and we are proud that we will be supplying low cost US made lithium from the Paradox Basin to LG Energy Solution a leading global manufacturer of lithium-ion batteries for electric vehicles, mobility, IT, and energy storage systems."About Anson Resources LtdAnson Resources (ASX:ASN) is an ASX-listed mineral resources company with a portfolio of minerals projects in key demand-driven commodities. Its core asset is the Paradox Lithium Project in Utah, in the USA. Anson is focused on developing the Paradox Project into a significant lithium producing operation. The Company's goal is to create long-term shareholder value through the discovery, acquisition and development of natural resources that meet the demand of tomorrow's new energy and technology markets.www.ansonresources.com Follow us on Twitter @anson_irForward Looking Statements: Statements regarding plans with respect to Anson's mineral projects are forward looking statements. There can be no assurance that Anson's plans for development of its projects will proceed as expected and there can be no assurance that Anson will be able to confirm the presence of mineral deposits, that mineralisation may prove to be economic or that a project will be developed.Competent Person's Statement 1: The information in this announcement that relates to exploration results and geology is based on information compiled and/or reviewed by Mr Greg Knox, a member in good standing of the Australasian Institute of Mining and Metallurgy. Mr Knox is a geologist who has sufficient experience which is relevant to the style of mineralisation under consideration and to the activity being undertaken to qualify as a "Competent Person", as defined in the 2012 Edition of the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves and consents to the inclusion in this report of the matters based on information in the form and context in which they appear. Mr Knox is a director of Anson.SOURCE: Anson Resources Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月23日 - (亚太商讯 via SeaPRwire.com) – 若要评选今年港股市场中表现最突出的板块，创新药无疑占据一席之地。在政策暖风持续吹拂下，港股18A公司整体走势强劲。根据WIND数据，截至2025年9月22日收盘，君圣泰医药（2511.HK）年内累计涨幅超过233.07%，成为市场中一道亮眼的风景线。股价强劲表现的背后，是资本市场对公司创新实力的高度认可。在全球医药创新不断推进的背景下，君圣泰医药深耕代谢性疾病领域，依托核心产品HTD1801独特的"一药多效"特性，正在心肾代谢综合征（Cardiovascular-Kidney-Metabolic Syndrome, CKM）治疗领域引领一场静默的范式变革。该药物在多适应症拓展、作用机制创新及商业化推进等方面接连实现突破，显示出可观的临床价值和市场前景。值得深思的是，在当前竞争日趋激烈的降糖药物市场中，君圣泰医药何以突破重围，实现从单一"降糖药企"到"心肾代谢领军企业"的跨越式蜕变？背后的投资逻辑是什么？图表一：公司股价走势图数据来源：WIND，格隆汇整理 数据截至2025年9月16日收盘HTD1801：CKM领域的"一药多效"破局者从市场空间看，君圣泰医药正切入一个被长期低估的千亿级市场--心肾代谢综合征（CKM）领域，该领域存在显著的未满足临床需求。CKM是一种涉及多器官交互的复杂疾病状态，涵盖心脏疾病、慢性肾病（CKD）以及多种代谢紊乱，如2型糖尿病、肥胖和血脂异常等。其病理机制复杂，患者常同时面临心、肾功能异常、高血糖、高血压、脂代谢异常和慢性炎症等多重威胁。据公司中期报告及临床资料显示，2032年全球代谢疾病市场规模将达到4580亿美元。CKM在全球影响近90%的美国成年人和80%的中国成年人，其中糖尿病患者人数已接近5.9亿。尤其在中国，糖尿病肾病（DKD）已成为导致终末期肾病的主要原因之一，而现有标准治疗在逆转肾功能衰退和全面控制代谢异常方面仍存在明显局限。面对这一巨大治疗空白，君圣泰医药的核心产品HTD1801通过独特的"AMPK激活 + NLRP3抑制"双重机制，展现出系统性的治疗优势。AMPK是细胞能量调节的核心靶点，激活后能够改善糖脂代谢并提升胰岛素敏感性；NLRP3则是炎症小体的关键组成部分，抑制后可显著降低全身炎症水平。该双靶点协同机制精准打击胰岛素抵抗这一共同病理基础，在多项临床研究中展现出抗炎及心肾保护的多维度收益。近期多项临床数据的披露，进一步夯实了HTD1801"一药多效"的综合价值。目前，HTD1801正在全球范围内开发，用于治疗CKM相关疾病，包括2型糖尿病(T2DM)、代谢相关脂肪性肝炎(MASH)、慢性肾病(CKD)、肥胖症、原发性硬化性胆管炎(PSC)及严重高甘油三酯血症(SHTG)。其中，在2型糖尿病方向，公司在行业顶尖学术年会上展露头角，展现出单药以及联合用药的优异表现。2025年6月美国糖尿病协会（ADA）年会公布的III期SYMPHONY 1研究显示，HTD1801单药治疗T2DM患者24周后HbA1c降低1.3%（基线≥8.5%亚组达1.5%），显著改善血脂（LDL-C及non-HDL-C）、炎症标志物（hs-CRP、GGT），并降低10年冠心病发生风险。2025年9月欧洲糖尿病研究协会（EASD）年会上，公司发布的III期SYMPHONY 2研究证实，在二甲双胍控制不佳的T2DM患者中，HTD1801联合二甲双胍治疗24周后HbAc1的最小二乘（LS）均值变化为 -1.21%，显著优于安慰剂（LS均值差异 -0.53%，p＜0.0001），同时餐后血糖、空腹血糖、心血管、肾脏等指标均获显著改善。两项数据披露的背后，展现出HTD1801这款全球首创的抗炎代谢调节剂不仅作为单药或联合二甲双胍治疗均显示出强劲降糖效果，更展现出超越血糖的心肾代谢综合获益。这使得HTD1801的想象空间从传统的降糖药，拓展为一个可能用于治疗整个心肾代谢系统（CKM）的综合性药物。尤为值得关注的是，HTD1801在慢性肾病（CKD）领域同样展现出治疗潜力。临床III期的事后分析显示，在合并轻度肾损伤（eGFR基线 60–89 mL/min/1.73m²）的T2DM患者中，HTD1801可显著改善eGFR，且未引起血钠、血钾等电解质紊乱，提示其良好的肾脏安全性及治疗潜力。临床前研究也进一步证实，HTD1801可改善肾功能标志物如血肌酐、尿素氮等指标。基于这些积极信号，公司已明确规划推进HTD1801用于CKD的II期临床研究。同时，2025年8月与中国医学科学院医药生物技术研究所达成合作，共同开展"糖尿病伴慢性肾病（CKD with T2DM）"的机制与临床研究，这一举动不仅有望拓宽HTD1801的适应症边界，更凸显公司通过产学研协同深化CKM整体治疗战略的意图。图表二：HTD1801通过多重机制维持代谢稳态数据来源：公司公告，格隆汇整理从临床到商业：君圣泰医药的升维之战开启从公司整体布局来看，君圣泰医药的未来发展远不止于当前成果，市场想象空间正在进一步打开。首先，公司研发投入持续加强，管线协同效应显著。根据中报数据，君圣泰医药在报告期内研发投入达1.064亿元，项目保持高效推进。目前公司拥有7款候选药物，覆盖10种适应症。其中HTD1801作为核心产品，正在全球开展多项中后期临床试验。这种"一药多适应症"的矩阵式布局，不仅最大化发挥了HTD1801的多机制优势，也显著提升了研发效率和资金使用效能。其次，2025年成为君圣泰医药的商业化元年，价值兑现在即，"一药多效"治疗新范式正稳步落地。根据公司规划，T2DM适应症即将正式启动新药上市申请（NDA），伴随申报进程推进，其商业潜力有望快速释放。在CKD领域，II期研究已在筹备中；此外，HTD1801与GLP-1RA联合用于肥胖治疗显示出协同减重和肌肉保护效应，相关II期研究也在积极推进中，进一步拓展了其联合用药的想象空间。图表三：公司管线情况数据来源：公司公告，格隆汇整理最后，从估值层面看，公司有望迎来价值体系重构。尽管当前股价部分反映了HTD1801在T2DM领域的潜力，但其在心肾代谢（CKM）这一更广阔赛道中的价值尚未被充分定价。凭借"一药多效"的独特优势，HTD1801有望成为CKM的基础治疗药物之一。随着CKM相关临床数据的持续读出和适应症的不断拓展，君圣泰医药有望从单一代谢疾病药企，跃升为心肾代谢领域的龙头公司，驱动整体估值体系重构。小结在国家鼓励源头创新、中医药现代化政策支持的大背景下，HTD1801基于传统天然产物（熊去氧胆酸与小檗碱）进行结构优化，兼具"异病同治、标本兼治"的中医理念与现代国际临床开发标准，具备较强的文化认同与政策适配性。当众多药企仍扎堆于GLP-1等红海领域时，君圣泰医药凭借HTD1801的"一药多效"优势，已悄然切入心肾代谢这一系统性疾病市场。其升维之战，才刚刚开始。文章来源：格隆汇 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

波兰莫西纳和佛罗里达州西棕榈滩, 2025年9月23日 - (亚太商讯 via SeaPRwire.com) - 作为美国马球协会（USPA）的官方运动品牌， U.S. Polo Assn. 自豪地支持了第十五届国际马球联合会（FIP）欧洲马球锦标赛。该赛事于8月26日至9月7日在波兰莫西纳著名的Sowiniec马球俱乐部隆重举行。这已是该运动品牌第五次担任这一两年一度盛事的官方服装合作伙伴。第十五届国际马球联合会欧洲马球锦标赛冠军U.S. Polo Assn. 为球员和裁判提供了特别设计的高性能球衣和品牌帽款，并在场地设置品牌标识和互动体验，为赛事观众带来品牌的真实感与运动灵感风格。该运动品牌是国际马球联合会（FIP）的官方服装合作伙伴，而FIP亦被国际奥林匹克委员会认可为举办国际马球赛事的官方机构。在第十五届FIP欧洲马球锦标赛中，共有八支队伍参赛。激动人心的决赛中，西班牙队以7.5比4的比分力克瑞士队，赢得了这项备受瞩目的欧洲冠军。这是西班牙队连续第二次在FIP欧洲马球锦标赛中夺冠。该队还曾在2022年于美国佛罗里达州惠灵顿的USPA国家马球中心（NPC）举办的第十二届FIP世界马球锦标赛中摘得桂冠。“U.S. Polo Assn. 作为第十五届国际马球联合会欧洲马球锦标赛官方服装合作伙伴的支持，充分体现了我们作为全球运动品牌所秉持的一切价值。” USPA Global首席执行官兼总裁J. Michael Prince表示。USPA Global是管理这一价值数十亿美元的U.S. Polo Assn. 全球品牌的公司。他补充道：“我们很荣幸能够参与这样一个重要的国际体育盛事，尤其是本届欧洲马球锦标赛首次在波兰举办，意义非凡。”Prince还表示：“我们计划于2026年初将U.S. Polo Assn. 品牌引入波兰，让当地消费者亲身体验这一运动灵感品牌。”除了U.S. Polo Assn. 之外，第十五届FIP欧洲马球锦标赛还吸引了众多知名赞助商，包括《Vogue》波兰版、Royal Salute苏格兰威士忌、泰亭哲香槟、Antonius鱼子酱、Defender、Plucinski 1906等，共同为Sowiniec马球俱乐部的赛事增添了高端奢华的氛围。“在过去九年里，U.S. Polo Assn. 一直是国际马球联合会的重要合作伙伴，帮助提升了我们最重要赛事的知名度和专业水准。” FIP执委会成员Alex Taylor表示。“该品牌的支持在促成欧洲马球锦标赛落地波兰方面发挥了关键作用。波兰不仅拥有深厚的马球传统，也拥有不断壮大的运动员和体育爱好者群体。”第十五届FIP欧洲马球锦标赛自1993年首次举办以来，本届赛事为波兰马球百余年的历史（可追溯至1911年）带来了新的聚光灯。如今，波兰已拥有近百名活跃球员，兴趣不断增长，成为这一重大国际体育盛事令人振奋的新东道主。图片来源：Andrzej Olszanowski关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 为美国马球协会（USPA）之官方品牌，该协会创立于 1890 年，是北美最大马球俱乐部与马球运动员联盟。今年，U.S. Polo Assn. 与美国马球协会（USPA）共同庆祝品牌成立 135 周年，持续从体育汲取灵感。 U.S. Polo Assn. 拥有数十亿美元的全球品牌价值，并透过逾 1,100 间品牌零售店及数千个销售据点，在全球超过 190 个国家提供男装、女装、童装、配件与鞋类产品。透过与美国 ESPN、欧洲的TNT和印度 Star Sports 的历史性协议，U.S. Polo Assn. 赞助的多项世界顶级马球赛事首次转播至全球数百万体育迷，让这项激动人心的运动登上世界舞台。据《License Global》报导，U.S. Polo Assn. 长期被评为全球顶尖体育授权品牌之一，与 NFL、PGA Tour 和 Formula 1 并列。此外，该品牌亦因于全球及数位市场的成长，获得多项国际奖项肯定。 U.S. Polo Assn. 曾登上《富比士》、《财富》、《现代零售》和《GQ》等主流媒体，也多次出现在 Yahoo Finance 与 Bloomberg 等财经平台。欲了解更多资讯，请造访 uspoloassnglobal.com 并追踪 @uspoloassn。USPA Global 为 USPA 子公司，负责营运全球价值数十亿美元之 U.S. Polo Assn. 品牌。USPA Global 亦营运提供体育与生活风格内容的 Global Polo TV。要了解更多信息，请访问 globalpolo.com 或在 YouTube 上搜索 Global Polo。关于国际马球联合会（FIP）国际马球联合会（FIP）获国际奥林匹克委员会（IOC）认可，是代表马球运动的全球性组织。FIP的使命是推动、发展并规范马球运动在全球范围内的开展。联系信息Stacey KovalskyVP, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036Shannon StilsonVP, Sports Marketing and Mediasstilson@uspagl.com+001.561.227.6994来源: U.S. Polo Assn. Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MOSINA, POLAND AND WEST PALM BEACH, FL, Sept 23, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the XV Federation of International Polo (FIP) European Polo Championship, held from August 26 to September 7 at the prestigious Sowiniec Polo Club in Mosina, Poland. The sports brand served for the fifth time as the Official Apparel Partner of this prestigious event, which is played every two years.XV Federation of International Polo European Polo Championship WinnersU.S. Polo Assn. outfitted players and umpires in custom-designed performance jerseys and branded caps, alongside field signage and branded on-site activations for event attendees, bringing the brand's authenticity and sport-inspired style to the tournament. The sports brand is the Official Apparel Partner of FIP, which the International Olympic Committee recognizes to host international polo competitions.Eight teams competed throughout the XV FIP European Polo Championship, and the thrilling final game concluded with Spain taking the coveted European title in a hard-fought victory over Switzerland, with a final score of 7.5 - 4. This is the second consecutive win for Spain in the FIP European Polo Championship. The team also won the XII FIP World Polo Championship in 2022, hosted at the USPA National Polo Center (NPC) in Wellington, Florida."U.S. Polo Assn.'s support of the XV Federation of International Polo European Polo Championship as the Official Apparel Partner exemplifies everything we stand for as a global sports brand," said J. Michael Prince, CEO and President of USPA Global, the company that manages the global, multi-billion-dollar U.S. Polo Assn. brand. "We are honored to be part of such an important international sporting moment, especially as the XV European Polo Championship arrived in Poland for the first time in history.""We are also planning to bring the U.S. Polo Assn. brand to Poland in early 2026 for consumers in the region to experience the sport-inspired brand," Prince added.In addition to U.S. Polo Assn., the XV FIP European Polo Championship featured many high-profile sponsors, including Vogue Poland, Royal Salute Scotch Whisky, Taittinger Champagne, Antonius Caviar, Defender, Plucinski 1906, and others, all contributing to the event's elevated and luxurious atmosphere at Sowiniec Polo Club."U.S. Polo Assn. has continued to be a standout partner to the Federation of International Polo for the past nine years, helping to elevate the visibility and professionalism of our most important tournaments," said Alex Taylor, Executive Board Member of FIP. "The brand's support has been instrumental in bringing the European Polo Championship to Poland, a country with a rich polo legacy and a growing community of athletes and sports fans."The XV FIP European Polo Championship, first held in 1993, brought a vibrant spotlight to Polish polo's century-old history, which dates back to 1911. Today, with nearly 100 active players and a growing interest, Poland served as an exciting new host for this major international sporting event.Photo Credit: Andrzej OlszanowskiAbout U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About the Federation of International Polo (FIP)Recognized by the International Olympic Committee (IOC), the Federation of International Polo (FIP) is the global organization representing the sport of polo. FIP's mission is to promote, develop, and regulate the sport of polo internationally.Contact InformationStacey KovalskyVP, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036Shannon StilsonVP, Sports Marketing and Mediasstilson@uspagl.com+001.561.227.6994SOURCE: U.S. Polo Assn. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BUSAN, SOUTH KOREA, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – “Hong Kong Cinema @ BUSAN 2025” – a promotional campaign jointly organised by the Cultural and Creative Industries Development Agency (CCIDA) of the Culture, Sports and Tourism Bureau (CSTB) of the Hong Kong SAR Government, the Hong Kong Film Development Council (FDC) and the Hong Kong Trade Development Council (HKTDC) – was held from 20 to 23 September at the Asian Contents & Film Market (ACFM) in Busan, South Korea.  The campaign included exhibitions and networking activities that helped promote Hong Kong film production, strengthening Hong Kong's position as an East-meets-West centre for international cultural exchange and as a regional intellectual property trading centre. Additionally, the campaign showcased the latest works from Hong Kong and provided a platform for local filmmakers to interact with international industry peers and explore collaboration opportunities.HKTDC Deputy Executive Director Patrick Lau stated: “We are pleased that the HKTDC co-organised ‘Hong Kong Cinema @ BUSAN 2025’ this year, teaming up once again with the local film industry to showcase the industry’s vitality and creativity to overseas counterparts. We aim to build an international exchange platform so local filmmakers can engage with their overseas peers, helping them understand the latest global market trends and gain crucial industry information in an ever-changing environment. Through flexible adaptation, filmmakers can explore new realms of innovation.”Hong Kong delegation deepens international industry exchangeA Hong Kong Night was held at the Paradise Hotel Busan on 19 September, marking the start of “Hong Kong Cinema @ BUSAN 2025”. The event drew over 600 industry professionals from Hong Kong and around the world, creating opportunities for future collaboration.Members of the Hong Kong delegation included Sylvia Chang, producer of Hong Kong film Measure in Love, director Siu-Ping Kung and actress Angela Yuen, as well as Hong Kong producers Johnny Wang, Terence Choi, Fanny Chong and Kinnie Cheung. Sylvia Chang was awarded the “Camellia Award” by the Busan International Film Festival, in recognition of her outstanding achievements as a female filmmaker.In addition to attending various exchange activities organised by the Hong Kong side, Hong Kong producers participated in official ACFM events, such as the Producer Hub. These events also included luncheons, panel discussions and networking sessions, strengthening connections with overseas producers and production companies, while creating opportunities to explore cross-border collaboration.Exhibition and networking activities propel international cooperationA Hong Kong Pavilion, funded by the CCIDA and the Film Development Fund (FDF), was set up at the ACFM. Participating Hong Kong film production and distribution companies included Cappu Films Limited, Golden Network Asia Limited, Mei Ah Entertainment Group Ltd, One Cool Pictures Limited and Mandarin Motion Pictures Limited.Additionally, other visiting Hong Kong film companies and organisations included 32cc Limited, Edko Films Limited, Emperor Motion Pictures, Entertaining Power Co. Limited, Golden Scene Company Limited, the Asian Film Awards Academy and the Industry Office of the Hong Kong International Film Festival Society.The Hong Kong Pavilion also showcased Hong Kong films that had been selected for the 30th Busan International Film Festival. These included: The Shadow's Edge, in the Open Cinema section; Measure in Love, funded by the Directors’ Succession Scheme under the FDF, in the Open Cinema section; and Girlfriends, in the Vision - Asia section.Hong Kong and South Korea forge new path with MoU to strengthen collaboration in film talent developmentDuring the event, CCIDA signed a memorandum of understanding (MoU) with the Busan Asian Film School, with an aim to strengthen collaboration between Hong Kong and South Korea in activities and exchanges to nurture film talents.HTKDC shared market insightsRepresentatives from the HKTDC also attended the official summit of the ACFM, the Asian Film Market Leaders Summit. At the Summit, Josephine Lam, Section Head of HKTDC’s Entertainment Industry, Service Promotion Department, engaged in discussions with representatives from major Asian film markets, such as Busan’s ACFM, the Tokyo International Film Festival Content Market (TIFFCOM), the Taiwan Creative Content Fest (TCCF), the Jogja-NETPAC Asian Film Festival (JAFF Market) and the Red Sea Souk in Saudi Arabia. Ms Lam also shared insights from the Hong Kong International Film & TV Market (FILMART), highlighting its role as one of Asia's primary film markets.Several participating companies expressed satisfaction with “Hong Kong Cinema @ BUSAN 2025”, stating that the campaign successfully showcased the strengths of Hong Kong's film industry to overseas markets. They also noted that the campaign facilitated increased collaboration and exchange between Hong Kong filmmakers and their international counterparts.Photo download: http://bit.ly/3IDqJBRThe Hong Kong Pavilion, funded by the CCIDA and the FDF, is set up at the ACFMGuests attending Hong Kong Night included Sylvia Chang, producer of Hong Kong film Measure in LoveIrene Yuen (left), Head (Film Promotion and Facilitation) of the CCIDA, and Kang Sung Kui (right), Director of the Busan Asian Film School, signed a Memorandum of Understanding (MoU)Hong Kong producers Johnny Wang, Terence Choi, and Kinnie Cheung engaged in exchanges with international industry professionals at Producer Hub of the ACFMJosephine Lam, Section Head of HKTDC’s Entertainment Industry, Service Promotion Department, shared market insights at the Asian Film Market Leaders SummitMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395          Email: johnny.cy.tsui@hktdc.org  About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedInAbout CCIDACultural and Creative Industries Development Agency (CCIDA) (formerly known as Create Hong Kong) was set up in 2009 as a dedicated agency to lead, champion and drive the development of our creative industries.  It also serves as the secretariat of the CreateSmart Initiative and the Film Development Fund.To further promote the development of arts, culture and creative sectors as industries, the Government of the Hong Kong Special Administrative Region completed the restructuring of Create Hong Kong as CCIDA on 14 June 2024 pursuant to the 2023 Policy Address.  CCIDA is playing a more proactive and positive role to strengthen its support for the development of the arts, cultural and creative sectors, including identifying opportunities for the relevant industries and leading creative industries to arrange delegations to various showcases worldwide, thereby exporting Hong Kong’s cultural and creative industries including film, advertising, architecture, design, digital entertainment, music, printing and publishing, and television.About HKFDCIn his Policy Address in October 2006, the Chief Executive announced that the then Secretary for Commerce, Industry and Technology will co-ordinate the film-related policy, planning and activities, including manpower training, Mainland and overseas promotion, and filming support.  From 1 July 2022 onwards, the relevant work is co-ordinated by the Secretary for Culture, Sports and Tourism. In order to support the Secretary and to ensure the policy is in line with the sustainable development of the film industry, the Government established the Hong Kong Film Development Council (HKFDC) on 15 April 2007.The Film Development Fund (FDF) was first set up by the Government in 1999 to support projects conducive to the long-term development of the film industry in Hong Kong.  Since 2005, the Government has injected a total of about $2.9 billion into the FDF to support Hong Kong film industry along four strategic directions, namely nurturing talent, enhancing local production, expanding markets and building audience. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月23日 - (亚太商讯 via SeaPRwire.com) – 大洋集团控股有限公司（「大洋集团」或「集团」；股份代号：1991.HK）欣然宣布，为把握Web4.0发展机遇，进一步推进其AI与数字化转型战略，公司目前正考虑一项潜在供股计划，计划募集资金用于AI数字人的研究与开发、建立真实世界资产（「RWA」）的底层资产组合及链上方案构建、购买战略性数字资产如以太坊（「ETH」）等加密货币作为新业务所需储备等，与集团向Web4.0战略转型以及RWA生态布局的前期工作相关。此潜在供股计划可望为集团于8月所宣布向助力企业或机构进行之AI与数字化转型业务发展之战略方向提供财务支持，比如在建立核心数字资产池、加速AI数字人技术研发及深化RWA生态布局等方面。同时，潜在供股可为集团带来新资金及资源以坚实财务基础，赋能大洋集团紧抓其面向的教育、游戏、大健康三大万亿赛道行业的数字化转型所带来的长远机遇。大洋集团主席施琦女士表示：「是次潜在供股计划对于大洋集团迈向数字经济新时代有着至关重要的积极正面意义。我们正经历资本革新、到技术革新、再到业态革新的脱变过程，恰恰与我们早前公布的转型蓝图相辅相成。相信潜在供股的机会将使我们抢占Web4.0发展先机，加快RWA领域布局，未来有望拓展包括AI数字人服务付费、数字人IP交易、RWA生态服务在内等新收入来源。我们感谢股东一直以来的支持，并坚信此符合战略规划的举动将为股东创造长期且可观的回报。」关于大洋集团控股有限公司(股份代号: 1991)大洋集团控股有限公司（股票代号：1991）成立于 1991 年，2007 年在香港联合交易所有限公司成功上市，是一家兼具三十年产业积淀与前瞻数字视野的多元化企业。自创立以来，集团早期聚焦硅胶输入设备领域，专业设计及制造用于消费电子装置、计算器、笔记本计算机、手提电话及汽车周边产品的核心部件，凭借高度整合的生产体系、严苛的质量管控与技术创新能力，赢得全球众多知名品牌客户的长期信赖，奠定了坚实的产业根基。随着全球数字化转型浪潮的深化，大洋集团敏锐洞察数字经济时代的战略机遇，果断启动向 Web4.0 领域的全方位战略转型，以「拥抱技术变革、重构价值生态」为核心方向，精准锚定人工智能（AI）、真实世界资产（RWA）代币化及香港政策生态三大核心驱动力，致力于打通 「数据 — 资产 — 价值」 的转化链路，开启从传统制造向数字经济领航者的跨越。当前，大洋集团正以 Web4.0 战略转型为新起点，聚焦教育、游戏、大健康三大万亿赛道，致力于成为亚太地区 AI 与 RWA 双赛道的领先企业，为全球投资者、合作伙伴及个人用户提供高效的价值增长生态，持续推动全球数字经济高质量发展，写下从「产业深耕者」到「数字生态构建者」的全新一页。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – Ta Yang Group Holdings Limited ("Ta Yang Group" or the "Group"; Stock Code: 1991.HK) is pleased to announce that, to seize the opportunities of Web 4.0 and further advance our AI and digital transformation strategy, the Group is currently considering a potential rights issue. The proposed fundraising would be used for the research and development (“R&D”) of AI digital human technologies, the establishment of real-world asset (“RWA”) profolilo and the framework for on-chain solutions, and the acquisition of strategic digital assets, such as cryptocurrencies like Ethereum (“ETH”) as reserves, all of which are aligned with the Group’s strategic transformation towards Web 4.0 and the buildout of the RWA ecosystem.This potential rights issue is expected to provide financial support for the strategic direction announced by the Group in August, supporting enterprises and institutions in their AI and digital transformation initiatives. This includes establishing a core digital asset pool, accelerating the R&D of AI digital human technologies, and deepening the RWA ecosystem. At the same time, the potential rights issue would bring in fresh capital and resources to strengthen the Group’s financial foundation, empowering the Group to capture long-term opportunities arising from the digital transformation of the trillion-dollar industries it targets: education, gaming, and healthcare.Chairlady of Ta Yang Group, Ms. Shi Qi commented: “The potential rights issue carries crucial positive significance for the Group as it advances into the new era of the digital economy. We are undergoing a transformation from capital innovation to technological innovation and ultimately to business model innovation, a process that complements the transformation blueprint we announced earlier. We believe this potential rights issue will enable us to seize a first-mover advantage in Web 4.0 development, accelerating our move towards RWA field and is expected to open up new revenue streams in future, including paid AI digital human services, digital human IP trading, and services of the RWA ecosystem. We are grateful for the continued support of our shareholders and are confident that this strategic move, aligned with our long-term plan, will generate substantial and sustainable returns for them.”About Ta Yang Group Holdings Ltd. (Stock Code: 1991.HK)Founded in 1991 and listed on the Hong Kong Stock Exchange in 2007, Ta Yang Group Holdings Limited (Stock code: 1991.HK) combines thirty years of industry expertise with forward-looking digital vision as a diversified enterprise. The Group initially focused on silicone input devices, designing and manufacturing core components for consumer electronics, computers, laptops, mobile phones, and automotive accessories. Leveraging integrated production systems, strict quality controls, and technological innovation, Ta Yang Group has earned the long-term trust of leading global brands and established a solid industrial foundation.With the acceleration of global digital transformation, Ta Yang Group keenly recognized strategic opportunities in the digital economy era and decisively launched a full-scale strategic transition to Web 4.0, adopting “embracing technological change, reconstructing value ecology” as its core direction, focusing on AI, RWA tokenization, and Hong Kong policy ecosystem as its three chief drivers. Committed to forging a “Data—Asset—Value” transfer chain, the Group is transitioning from traditional manufacturing to a leader in the digital economy.At present, Ta Yang Group is embracing Web 4.0 transformation as a new starting point, focusing on education, gaming, and healthcare as three trillion-dollar tracks, aiming to become a leading AI and RWA dual-sector player in Asia-Pacific, delivering highly efficient value-growth ecosystems to global investors, partners, and individuals, and continuously advancing the high-quality development of the global digital economy—writing a new page from ”industrial cultivator” to ”digital ecosystem builder”. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Sept 23, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.More information about Vecantoxatug and TetanusVecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc). TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, - tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)2), and human tetanus immunoglobulin (HTIG) - face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.More information about Silevimig and RabiesSilevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.About GENRIX BIOGenrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.Reference:1. China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.0012. Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People's Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.0013. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf4. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.0045. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdfCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳，2025年9月23日 - (亚太商讯 via SeaPRwire.com) – 康哲药业控股有限公司（"康哲药业"）欣然宣布，于2025年9月22日，通过其附属公司与重庆智翔金泰生物制药股份有限公司（"智翔金泰"）就两款1类治疗用生物制品分别签订独家合作协议（"协议"），分别为用于破伤风的被动免疫适应症的唯康度塔单抗（GR2001）注射液（"唯康度塔单抗注射液"）以及用于疑似狂犬病病毒暴露后的被动免疫适应症的斯乐韦米单抗（GR1801）注射液（"斯乐韦米单抗注射液"）。根据协议，康哲药业获得上述两款产品在中国大陆的独家商业化权与除中国大陆之外的亚太地区及中东、北非的独家许可权，合作期限至两款产品分别在中国大陆地区获批上市后十年（各产品的初始期限），各产品的初始期限到期后除非发生协议约定的终止或解除情形，则协议每十年自动延期。唯康度塔单抗注射液是一款安全性佳，且优效于破伤风人免疫球蛋白（HTIG），可为患者提供快速且持久保护的被动免疫制剂。唯康度塔单抗注射液用于破伤风的被动免疫适应症的Ⅲ期临床试验达到了主要疗效终点。2024年5月，唯康度塔单抗注射液被国家药品监督管理局（NMPA）药品审评中心（CDE）纳入突破性治疗品种名单，其新药上市申请（NDA）已于2025年5月22日获得CDE受理。斯乐韦米单抗注射液是全球首款针对狂犬病毒糖蛋白表位Ⅰ和/或III的重组全人源抗狂犬病病毒（Rabies Virus，RABV）双特异性抗体，符合世界卫生组织（WHO）建议开发的针对不同抗原位点的"鸡尾酒式"疗法，可大规模标准化稳定生产，并且中和谱广、免疫原性低、对疫苗主动免疫干扰小、成本可控。2025年1月14日, 其用于成人疑似狂犬病病毒暴露后的被动免疫适应症的NDA获CDE受理；此外，其针对2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫适应症的临床试验申请已于2025年7月获得NMPA批准，目前正在进行III期临床试验。康哲药业始终致力于布局具有临床价值及差异化优势的创新产品。破伤风和狂犬病的被动免疫市场广阔，现有被动免疫制剂在安全性及可及性上存在一定局限性。期待唯康度塔单抗注射液和斯乐韦米单抗注射液的获批上市，有望为破伤风及狂犬病暴露后患者带来新的被动免疫防治选择，并可与康哲药业在售产品在专家网络与市场资源方面协同，早日惠及广大患者。关于唯康度塔单抗注射液及破伤风的更多信息唯康度塔单抗注射液是一款由智翔金泰自主研发的重组人源化抗破伤风毒素(Tetanus Neurotoxin, TeNT)的单克隆抗体，作用靶点为TeNT的重链C端(TeNT-Hc)。TeNT是一条约150kDa的单链蛋白，经过翻译后修饰，形成由重链和轻链组成的活性毒素。唯康度塔单抗注射液能特异性结合TeNT-Hc，阻断其进入神经元细胞，起到被动免疫作用。唯康度塔单抗注射液在中国已取得授权专利。破伤风是由破伤风梭状芽孢杆菌通过伤口侵入人体引起的急性特异性感染，可发生于任何年龄段，在无医疗干预的情况下，尤其是老年人和婴幼儿，病死率接近100%。即使经过积极的综合治疗，该病的死亡率在全球范围仍高达30%至50% [1]。据估计，全球每年约有50万至100万例破伤风病例[1]。破伤风梭状芽孢杆菌广泛分布于土壤及环境中，并存在于哺乳动物的肠道中，通过破损的皮肤黏膜侵入人体，引起急性特异性感染，因此破伤风重在预防。目前临床常用的被动免疫药物（俗称"破伤风针"），包括破伤风毒素（TAT）、马破伤风免疫球蛋白（F(ab’) 2）、破伤风人免疫球蛋白（HTIG），但在安全性和可及性方面存在显著短板[2]，主要体现在易引起过敏，传播传染性病原风险，来源有限等问题，临床亟须新的防治药物。唯康度塔单抗注射液可提供优效于HTIG的保护力，展现出优异的安全性和耐受性，免疫原性低，且具备更强的可控性和可及性，有望为患者提供更佳的防治选择。关于斯乐韦米单抗注射液及狂犬病的更多信息斯乐韦米单抗注射液是一款由智翔金泰自主研发的重组全人源抗狂犬病病毒双特异性抗体，作用靶点为RABV的包膜糖蛋白（Glycoprotein，G蛋白），通过靶向结合G蛋白表位I和/或III，阻断其与受体的结合，在狂犬疫苗主动免疫完全发挥保护作用前阻滞病毒对神经的侵染，预防狂犬病。斯乐韦米单抗注射液的分子设计满足WHO关于抗狂犬病病毒抗体开发的建议——采用针对不同抗原位点的多株单抗组合成"鸡尾酒式"组合制剂，以保证对不同病毒株或病毒的不同基因型的有效性。斯乐韦米单抗注射液在中国已取得授权专利。斯乐韦米单抗注射液用于成人疑似狂犬病毒暴露后的被动免疫适应症的III期临床试验达到了主要疗效终点，研究显示斯乐韦米单抗注射液与目前我国主要被动免疫制剂狂犬病人免疫球蛋白（HRIG）具有非劣的保护力，在狂犬病毒暴露的早期提供即时保护，且不会对疫苗发挥主动免疫产生不利影响。狂犬病是由RABV感染引起的一种急性人畜共患病，临床大多表现为特异性恐风、恐水、咽肌痉挛、进行性瘫痪等[3]，病死率几乎为100%，是世界上最致命的疾病之一。目前对已经出现疾病症状的狂犬病没有公认有效的治疗方法，规范的暴露后预防（Post-Exposure Prophylaxis，PEP）处置是预防狂犬病的最有效策略[4]。PEP包括伤口处置、疫苗接种、按需注射被动免疫制剂。疫苗诱导产生抗体需要1-2周的时间，在第一针疫苗注射后至机体产生足量抗体（≥0.5IU/ml）之前，被动免疫制剂可为该高风险时段提供即时保护[3]。根据《狂犬病暴露预防处置工作规范(2023年版)》，狂犬病III级暴露后以及严重免疫功能缺陷的II级暴露病例应当在第1剂疫苗免疫同时给予被动免疫治疗[5]。我国全年狂犬病毒暴露人口数逾4,000万，其中40%为III级暴露，共1,600万人[3]。但出于患者认知、价格、可及性等原因，III级暴露者中，仅15%左右接受被动免疫制剂注射[3]。我国被批准上市的被动免疫药物有狂犬病人免疫球蛋白（HRIG）或马源抗狂犬病血清(Equine Rabies Antiserum，ERA)，以阻止病毒进入神经组织从而获得快速保护作用。HRIG需要不断从加强免疫的健康人群中获得，来源相对困难，价格昂贵，存在血源感染的潜在风险（如艾滋病，乙肝，丙肝等）；ERA属于异源蛋白，易导致不良反应（如血清病，过敏性休克等）[3]。除HRIG和ERA外，国内仅有两款抗狂犬病病毒抗体药物获批上市。斯乐韦米单抗注射液是全球首款用于狂犬病被动免疫的重组全人源双特异性抗体，符合WHO推荐的"鸡尾酒式"疗法，其上市有望给患者提供多方位保护。关于智翔金泰智翔金泰（股票代码：688443）成立于2015年，是一家以临床重大需求为导向，以抗体药物发现技术为驱动的创新型生物制药企业。公司聚焦自身免疫性疾病、感染性疾病和肿瘤三大治疗领域，持续开发单克隆抗体药物及双特异性抗体药物，拥有从抗体药物分子发现、工艺开发与质量研究、临床研究到大规模商业化的抗体药物全产业链布局。有关智翔金泰及其产品的更多资讯，请访问其官方网站：https://www.genrixbio.com/。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，其中皮肤健康业务已成为该细分领域的龙头企业，带来专科规模效率。同时，康哲药业持续深化东南亚及中东区域业务发展，助力高质量持续健康发展。参考文献/资料1. 中国创伤救治联盟，北京大学创伤医学中心. 中国破伤风免疫预防专家共识[J]．中华外科杂志，2018，56（3）：161-167．DOI: 10.3760/cma.j.issn.0529-5815.2018.03.0012. 中国医师协会急诊医师分会, 中国人民解放军急救医学专业委员会, 北京急诊医学学会, 等. 成人破伤风急诊预防及诊疗专家共识[J]. 临床急诊杂志, 2018, 19(12): 801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.0013. 中国疾病预防控制中心.《狂犬病预防控制技术指南（2016版）》. https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf4. 殷文武,王传林等. 狂犬病暴露预防处置专家共识[J].中华预防医学杂志,2019,53（7）：668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.0045. 中国疾病预防控制中心.《狂犬病暴露预防处置工作规范（2023年版）》. https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – On September 16th, the "Industrial Intelligent Water Saving and Efficiency Promotion Event & GreenTech WateRobot AI Agent 1.0 Ecosystem Launch", hosted by the China Industrial Energy Conservation and Cleaner Production Association, GreenTech Environment Co., Ltd., and Beijing Zhenghe Island Information Technology Co., Ltd., was successfully convened in Beijing.Centered on the theme "AI for Water Freedom", the event brought together nearly 400 industry experts, research institutions, universities, environmental protection enterprises, and financial institutions to witness the launch of the WateRobot AI Agent and explore the new developments in water savings and efficiency brought by AI agents to the industry.(Launch event scene)Wang Xiaokang, President of the China Industrial Energy Conservation and Cleaner Production Association, attended and addressed the event, noting that AI empowerment will unlock new possibilities for environmental governance and industrial water conservation, and that the WateRobot AI Agent is an innovative achievement of deep integration between intelligence and water technology. Liu Donghua, Founder and Chief Architect of Zhenghe Island, delivered a speech proposing that the resource utilization of wastewater can find optimal solutions through AI, and that the widespread application and continuous upgrading of the WateRobot AI Agent can inject significant strength into achieving "Water Freedom" for industry, cities, and even the nation.The event invited AI expert Wei Kai, Director of the Artificial Intelligence Research Institute at the China Academy of Information and Communications Technology, to deliver a keynote speech on "Artificial Intelligence+ Policies and Industrial Practices". He pointed out that advancements in large language models have brought new paradigms to the development of AI technology, and the birth of the WateRobot AI Agent represents an important attempt of AI in the field of industrial water treatment.Subsequently, GreenTech officially launched the WateRobot AI Agent. Chairman Zhang Huichun proposed that using AI to replace human management of water plants can achieve industrial assembly line production, modular assembly, unmanned operation, and intelligent operation of water plants, replacing the traditional operational models of conventional engineered water plants. This leads to a 90% reduction in footprint, construction period, and operational staff, as well as a 50% reduction in Life Cycle Cost (LCC), ultimately enabling humanity to obtain Sustainable, Abundant, Reliable, and Affordable High-quality water (SARAH), achieving Water Freedom.(WateRobot AI Agent product interface)Wang Xiaoyu, General Manager of the Digital Technology Business Unit of GreenTech, further elaborated that the WateRobot AI Agent is an AI agent system capable of autonomous operation and completing target tasks. It not only incorporates GreenTech's self-developed process optimization forecasting and decision-making models but also integrates computer vision, auditory, infrared, and other perceptual AI models, as well as domestic large language inference models. Under the Online to Offline closed-loop logic, it directly delivers value to customers——safe, efficient, and optimally cost-operated unmanned water plants. The WateRobot AI Agent has already been applied in newater house water plant scenarios and is expected to expand to other water treatment plants, as well as industrial, agricultural, and municipal facilities, committed to enabling unmanned operation and innovative operational models across various fields.The event featured the unveiling ceremony of the "Artificial Intelligence Innovation Research Center" jointly established by GreenTech and Wuhan University. Zhang Liping, Deputy Director of the Industry-Academia-Research Cooperation Office of the Science and Technology Development Research Institute of Wuhan University, attended the unveiling and delivered a speech. Both parties will conduct in-depth technical research and industry applications focused on unmanned and intelligent operations. A roundtable dialogue on "AI + Industry" with the theme "AI's New Mission: Driving Industrial Restructuring and a Sustainable Future" was also held, where AI experts and various entrepreneurs discussed the application scenarios, value advantages, and future prospects of AI in the industrial field.GreenTech entered into strategic partnerships with the Finance Center for South-South Cooperation, Shanxi Xinzhou Economic Development Zone, CPIC Investment Management (H.K.), Wuhan Easy-Sight Technology Co.,Ltd., Green Technology (Shanghai) Agricultural Technology Co., Ltd., China Construction Eco-Development Co., Ltd., Beijing Boqi Electric Power Technology Co., Ltd., Beijing Zhenghe Island Information Technology Co., Ltd., and China Chemical Enterprise Management Association, among others, to jointly promote the application and promotion of the WateRobot AI Agent in the industry and various sectors domestically and internationally.The launch not only marked the debut of the WaterRobot AI Agent, a "new species" driving intelligent and green transformation in the industry but also envisioned the future of an intelligent water ecosystem——AI for Water Freedom. Through the innovative practices of GreenTech, the mission of "AI assisting industrial water savings and efficiency" has taken a solid step forward. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月23日 - (亚太商讯 via SeaPRwire.com) – 在功能饮料和健康饮品市场迅速成长的当下，国际品牌正通过产品创新与文化联结争夺新一代消费者。9月22日，IFBH Limited（"IFBH"，6603.HK）旗下品牌INNOCOCO正式推出两款新品电解质水，并宣布启用亚洲超人气偶像团体"时代少年团"作为其首位品牌代言人。新品发布与代言人签约的背后，折射出IFBH正在从单一椰子水品牌向多元产品矩阵拓展，加速打造第二增长曲线。 持续丰富产品矩阵，夯实营收韧性长期以来，IFBH依托泰国优质原料与成熟供应链，以"if"椰子水和Innococo 100%椰子水在亚洲市场树立了天然健康饮品标杆，深受消费者认可。按零售额计，IFBH已连续多年稳居中国内地椰子水饮料市场首位，同时也是全球椰子水饮料市场第二大公司。在稳固椰子水市场领先地位的基础上，IFBH积极向其他饮料细分赛道拓展，主动开启产品多元化升级进程。新品电解质水的发布与品牌焕新，意味着INNOCOCO正从以往"真正椰子水的醇正口感，更健康"的品牌认知，转型为引领新一代功能性饮料的品牌，面向更广阔的市场需求。"这不仅仅是一次新品发布，更是一次品牌焕新" IFBH Limited（INNOCOCO品牌产品制造商与经销商）的首席执行官Pongsakorn Pongsak先生表示，"我们正从一个备受信赖的椰子水品牌，转型成为当今活力一代的贴心伙伴。通过"时代少年团"担任品牌代言人，我们将让INNOCOCO比以往任何时候都更贴近年轻消费者。"新品电解质水在配方上注入真实椰子水，富含维生素B族并提供双倍电解质，更快补水、更贴合运动与高能量场景，是对品牌基因的延伸与升级。同时，通过"时代少年团"这一亚洲超人气偶像团体的代言，INNOCOCO不仅获得广泛的年轻消费群体关注，也在文化层面完成了与Z世代、Alpha世代的对话，为产品在上市初期即打下品牌势能。从经营层面看，新产品线的加入，在强化IFBH核心业务优势的同时，丰富了收入来源，为公司构建起 "核心产品稳基盘、创新产品拓增量" 的增长格局，进一步增强公司营收韧性，提升长期估值。产品运营成效显著，强劲驱动资本市场表现在中国乃至亚太饮品市场品质化、多元化趋势日益明显的背景下，IFBH正以新品类、新代言和新渠道为支点，加速构建"产品创新+品牌赋能"的增长飞轮。INNOCOCO电解质水的推出和启动"时代少年团"代言，标志着IFBH在椰子水以外的功能性饮料领域迈出坚实一步。未来，随着新品推广、代言活动和渠道拓展逐步落地，IFBH有望在高端及功能性饮品赛道持续领跑，释放更大的业绩增长弹性。得益于公司经营成效的驱动，公司最近在资本市场上的表现也十分抢眼。近期，公司股价呈现强劲的上行态势，一度从最低点30港元，最高时成功触及40.26港元，涨幅相当可观。事实上，IFBH在产品运营与市方面的成效已经在中期业绩得到充分验证。2025年上半年，IFBH取得收益 9446万美元，同比增加 31.5%，增速明显跑赢行业平均水平；母公司拥有人应占溢利 1497.6 万美元；经调整溢利净额 1890 万美元，同比增加 13.9%。而新品发布与"时代少年团"代言等积极动作，有望进一步点燃资本市场对公司未来增长的憧憬。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com